Biomarkers /
ERBB3
Overview
Erb-b2 receptor tyrosine kinase 3 (ERBB3) is a gene that encodes a receptor tyrosine kinase in the epidermal growth factor family. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
ERBB3 is altered in 2.89% of all cancers with colon adenocarcinoma, bladder urothelial carcinoma, breast invasive ductal carcinoma, lung adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in ERBB3 are ERBB3 Mutation (2.53%), ERBB3 Amplification (0.30%), ERBB3 V104M (0.17%), ERBB3 E928G (0.12%), and ERBB3 V104L (0.10%) [3].
Clinical Trials
Significance of ERBB3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.